Tucatinib hemiethanolate (Irbinitinib hemiethanolate) is a potent, selective, and orally bioavailable HER2 tyrosine kinase inhibitor. It is utilized in preclinical and clinical research for metastatic HER2-positive cancers, including breast and colorectal cancer, demonstrating activity in both in vitro assays and in vivo models.
